CompletedNot Applicable

The Preliminary Effects of Henna on CIPN

Turkey (Türkiye)60 participantsStarted 2018-05-28

Plain-language summary

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxicities of chemotherapy. Though, CIPN is one of the common symptoms encountered by oncology nurses in care of patients. For this reason, there is a need for an intervention that could decrease or prevent of CIPN.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years and older women * Must the level of neurotoxicity is Stage II and Stage III * Must taken at least one chemotherapy cycle and is planned to continue 2 chemotherapy cycles * Be taking Folfox-6 chemotherapy protocol Exclusion Criteria: * Having an open wound and edema in the hands and feet * Having a peripheral neuropathy due to diabetes and autoimmune diseases * Using any complementary and alternative (CAM) treatment method to prevent peripheral neuropathy during administration

What they're measuring

Chemotherapy-Induced Peripheral Neuropathy Assessment Tool-CIPNAT

Timeframe: It was filled before the 2nd, 3rd and 4th chemotherapy cycles (each cycle is 15 days). Change from baseline Chemotherapy-Induced Peripheral Neuropathy Assessment Tool scores at 6 weeks.

Trial details

NCT IDNCT04201587

SponsorSelcuk University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06-14

View on ClinicalTrials.gov More Chemotherapy-induced Peripheral Neuropathy trials